Your current position:HOME > Products & Services > Tumor Gene Detection > Breast Cancer
Products & Services
Summary of Breast Cancer
 Due to the influence of work and living environment, for females, especially urban white-collar females, the probability of breast cancer becomes increasingly high. Breast cancer is the malignancy with the highest incidence for Chinese women. In China, more and more young females are attacked by breast cancer. According to the latest statistic data, new cases of breast cancer for female have reached 269,000 in 2015.

Scientific studies have verified that cancer is caused by the genetic mutation of human body, genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore in several kinds of cancers, it is regarded as the first choice of treatment for advanced cancer patients. At present, targeted drugs of breast cancer approved by FDA including Herceptin, Everolimus, Lapatinib, Palbociclib, etc. However, these drugs only apply for some types of breast cancer patients.

The precondition of the precise medical treatment is the accurate diagnosis. The concept of molecular classification allows doctors to make the best treatment scheme according to the different biomarkers carried by the patients of breast cancer and relevant clinical status, finds the potential targeted drug available to the greatest extent and improves the therapeutic efficiency of anti-cancer drugs. 

The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. As more and more driver genes of breast cancer targets have been found, the traditional single detection technology can’t meet the current detection needs. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.
Breast core™

Targeted medication guide gene detection of breast cancer

Buring Rock Breast core™, targeted at the patients with breast cancer, by applying the advanced second generation sequencing technology, can have a comprehensive detecting of drug-inhibited target genovariation related to breast cancer, provides comprehensive information for clinical individualized treatment, so as to realize the accurate treatment.

Genes covered in Breast core ™

Targeted drugs covered in Breast core™


More comprehensive individualized medication choice:

Breast core™ Comprehensively detects drug-inhibited target gene suggested in breast cancer NCCN guideline, drugs-inhibit target spot researched in the clinical trial of breast cancer stage Ⅱ/Ⅲ and approved drug-inhibited target spot in all kinds of cancers, provides the most comprehensive individualized medication genetic detecting of breast cancer;

More accurate gene mutation detection related to lung cancer:

The gene detection Panel based on the second generation sequencing technology optimized by Burning Rock Dx, can detect 4 types of variation types at one time (mutation, insertion and deletion, fusion, amplification, etc.), at the same time, applies ultra deep sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. On the one hand, the parallel detecting with the polygenic high sensitivity  improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; On the other hand, the complete coverage of exons can detect the hot spots and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation(such as KRAS and ALK point mutation),  having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.

More professional detection report interpretation:

Buring Rock Dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. The improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.

Applicable Populations


Sample Requirements

Operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.

Service Cycle

After sample inspection, detailed detection report will be issued in 10 natural days.

Service Procedure

Case Sharing
In update…